Prolonged induction activates Cebpα independent adipogenesis in NIH/3T3 cells

PLoS One. 2013;8(1):e51459. doi: 10.1371/journal.pone.0051459. Epub 2013 Jan 10.

Abstract

Background: 3T3-L1 cells are widely used to study adipogenesis and insulin response. Their adipogenic potential decreases with time in the culture. Expressing exogenous genes in 3T3-L1 cells can be challenging. This work tries to establish and characterize an alternative model of cultured adipocytes that is easier to work with than the 3T3-L1 cells.

Methodology/principal findings: INDUCED CELLS WERE IDENTIFIED AS ADIPOCYTES BASED ON THE FOLLOWING THREE CHARACTERISTICS: (1) Accumulation of triglyceride droplets as demonstrated by oil red O stain. (2) Transport rate of 2-deoxyglucose increased after insulin stimulation. (3) Expression of fat specific genes such as Fabp4 (aP2), Slc2a4 (Glut4) and Pparg (PPARγ). Among the cell lines induced under different conditions in this study, only NIH/3T3 cells differentiated into adipocytes after prolonged incubation in 3T3-L1 induction medium containing 20% instead of 10% fetal bovine serum. Rosiglitazone added to the induction medium shortened the incubation period from 14 to 7 days. The PI3K/AKT pathway showed similar changes upon insulin stimulation in these two adipocytes. C/EBPα mRNA was barely detectable in NIH/3T3 adipocytes. NIH/3T3 adipocytes induced in the presence of rosiglitazone showed higher 2-deoxyglucose transport rate after insulin stimulation, expressed less Agt (angiotensinogen) and more PPARγ. Knockdown of C/EBPα using shRNA blocked 3T3-L1 but not NIH/3T3 cell differentiation. Mouse adipose tissues from various anatomical locations showed comparable levels of C/EBPα mRNA.

Conclusions/significance: NIH/3T3 cells were capable of differentiating into adipocytes without genetic engineering. They were an adipocyte model that did not require the reciprocal activation between C/EBPα and PPARγ to differentiate. Future studies in the C/EBPα independent pathways leading to insulin responsiveness may reveal new targets to diabetes treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3-L1 Cells
  • Adipocytes / cytology
  • Adipocytes / drug effects*
  • Adipocytes / metabolism
  • Adipogenesis / drug effects*
  • Adipogenesis / genetics
  • Animals
  • Biological Transport / drug effects
  • Blotting, Western
  • CCAAT-Enhancer-Binding Protein-alpha / genetics*
  • CCAAT-Enhancer-Binding Protein-alpha / metabolism
  • Cattle
  • Cell Differentiation / drug effects
  • Cell Differentiation / genetics
  • Culture Media / chemistry
  • Culture Media / pharmacology*
  • Deoxyglucose / metabolism
  • Fatty Acid-Binding Proteins / genetics
  • Fatty Acid-Binding Proteins / metabolism
  • Gene Expression / drug effects
  • Hypoglycemic Agents / pharmacology
  • Insulin / pharmacology
  • Mice
  • Mice, Inbred C57BL
  • NIH 3T3 Cells
  • PPAR gamma / genetics
  • PPAR gamma / metabolism
  • RNA Interference
  • Reverse Transcriptase Polymerase Chain Reaction
  • Rosiglitazone
  • Serum
  • Thiazolidinediones / pharmacology
  • Time Factors
  • Triglycerides / metabolism

Substances

  • CCAAT-Enhancer-Binding Protein-alpha
  • Culture Media
  • Fabp4 protein, mouse
  • Fatty Acid-Binding Proteins
  • Hypoglycemic Agents
  • Insulin
  • PPAR gamma
  • Thiazolidinediones
  • Triglycerides
  • Rosiglitazone
  • Deoxyglucose

Grants and funding

Part of this work was funded by Tzu Chi University (TCIRP 96005-04Y1) and Buddhist Tzu Chi General Hospital (TCRD 101-20). The RNAi reagents obtained from Academia Sinica was supported by the National Research Program for Genomic Medicine Grants of NSC (NSC97-3112-B-001-016). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.